brief from someone at burnett yesterday

1. Hep E is one of Genelabs top products. They have based 2 sales people in China to push it. They had difficulty with the Chinese market in the past because of the inaccuracy of their Hep E diagnostic. Now they feel they will really be able to sell in China. Also, they believe that Chinese approval should be relatively straightforward. Although this can take up to 12 months, they feel it will be fast tracked because the key decision makers have already been involved in the research and they are keen to adopt this technology in China. Now that Genelabs has been bought out by a US company, it is not unreasonable to expect that they might go for FDA approval.

2. Although figures on Hep E were not mentioned, they do believe that Hep E alone justifies the current market cap.

3. Hep A is around 10 times market size of Hep E and add to that another multiple for the fact that it will be predominantly sold in developed countries as opposed to Hep E. (didn't mention what this number could be). So Hep A is very significant in terms of increasing SLT's value.

4. Another company has requested to enter the bidding war on Hep A and they have allowed more time for Hep A evaluation because they believe this company will add some good meat to the "auction"

5. This deal has made an impact on the local research industry connections of the Burnette and had a positive impact with Burnett staff - that their research is paying it's way and being used to help people. They have a very high regard for the SLT team in getting their research to market. Further, what we may see is that other research facilities in collaboration with the Burnett may follow Burnett's example of using SLT to commercialise their technologies as well.

6. Virus like particles program is very significant although it has not been newsworthy as investors and brokers did not want to hear any fluff - they wanted to hear Hep E deal is done.

7. Hep C showing excellent results in sensitivity - superior even to the Hep E.

8. Generally got the feeling that this is the bottom, very likely to improve significantly from here. Alot of blue sky even after the Hep E, A C